Skip to main content
MDLN
NASDAQ Industrial Applications And Services

Medline Reports Strong Q4 Sales Growth, Provides 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$50.01
Mkt Cap
$65.673B
52W Low
$38
52W High
$50.28
52W Position info
32% above low
Off High info
at 52W high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MDLN sits 32% above its 52-week low of $38.

Summary

Medline Inc. reported strong sales growth for Q4 and full year 2025, alongside a decrease in net income attributed to tariffs and IPO-related costs, while providing positive 2026 guidance.


Key Events · Earnings and Guidance · MDLN

  • Fourth Quarter 2025 Performance

    Net sales increased by 14.8% to $7.8 billion, while net income decreased by 37.7% to $180 million. Adjusted EBITDA was approximately flat at $805 million.

  • Full Year 2025 Performance

    Net sales grew 11.5% to $28.4 billion. Net income saw a slight decrease of 3.6% to $1.2 billion, but Adjusted EBITDA increased by 3.2% to $3.5 billion.

  • 2026 Financial Guidance

    The company expects full year 2026 organic sales growth of 8% to 9% and Adjusted EBITDA in the range of $3.5 billion to $3.6 billion.

  • Impact of Costs and IPO

    The decline in net income was primarily driven by higher costs of goods sold due to tariffs and increased operating costs, including investments in headcount and expenses related to the company's initial public offering.


Analysis · MDLN · Industrial Applications And Services

Medline Inc. announced its fourth quarter and full year 2025 results, showcasing robust sales growth but a decline in net income. The company's net sales increased by 14.8% in Q4 2025 and 11.5% for the full year, driven by increased volumes across both its Medline Brand and Supply Chain Solutions segments. While net income decreased, primarily due to higher costs of goods sold from tariffs and increased operating costs including IPO-related expenses and headcount investments, Adjusted EBITDA remained relatively stable in Q4 and grew for the full year. The company also provided 2026 guidance, projecting organic sales growth of 8% to 9% and Adjusted EBITDA between $3.5 billion and $3.6 billion, indicating continued operational strength and a positive outlook following its successful initial public offering.

At the time of this filing, MDLN was trading at $50.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $65.7B. The 52-week trading range was $38.00 to $50.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MDLN - Latest Insights

MDLN
Jul 09, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.85
Real-time Price: $39.90 info
Change: -$0.950 (-2%) info
Market Cap: $53.218B info
MDLN
Jul 08, 2026, 3:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $40.51
Real-time Price: $39.90 info
Change: -$0.610 (-2%) info
Market Cap: $53.218B info
MDLN
Jul 02, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $41.73
Real-time Price: $39.90 info
Change: -$1.83 (-4%) info
Market Cap: $53.218B info
MDLN
Jun 03, 2026, 9:36 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $33.37
Real-time Price: $39.90 info
Change: +$6.53 (+20%) info
Market Cap: $53.218B info
MDLN
Jun 02, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.94
Real-time Price: $39.90 info
Change: +$3.96 (+11%) info
Market Cap: $53.218B info